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High-dose melphalan (MEL) is the standard therapy for autologous stem cell transplantation (ASCT) in
multiple myeloma (MM), although the optimal conditioning regimen remains yet to be identiﬁed. Thiotepa
(THIO) appears to be a potentially effective option, with broad-spectrum antitumor efﬁcacy that can be added
to myeloablative multiagent regimens for ASCT in hematopoietic tumors. We conducted a phase II trial,
adding THIO (275 mg/m2) to high-dose MEL (140 mg/m2) before a second ASCT, in a tandem ASCT strategy,
in 64 patients with “de novo” MM. Overall, there was no transplant-related mortality. The incidence of
neutropenic fever and mucositis (grades 3 to 4) was 39% and 9%, respectively. Median number of days to
neutrophil and platelet engraftment were 11 and 12, respectively. After the second transplantation, the
complete response improved to 43.8%. Overall response rate was 86%. After a median follow-up of 18.1
months, 13 patients had progressed and 3 died from MM. Median progression-free survival was not reached,
and actuarial 2-year rates of progression-free and overall survival were 71% and 88.9%, respectively. Our
results suggest that THIO/MEL is a feasible and safe conditioning regimen for ASCT in MM and should be
explored for efﬁcacy in a phase III study.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION 2010s are characterized by studying the optimal combina-
Multiple myeloma (MM) is the hematological malignancy
in which clinical research has made the most signiﬁcant
progress in the past 20 years. Until 1980, only melphalan
(MEL) plus prednisone could improve the overall survival
(OS) of patients [1]. Subsequently, a French study showed
that the use of high-dose chemotherapy (HDC) with autol-
ogous stem cell transplantation (ASCT) could make a differ-
ence in treatment [2]. In the 2000s, a dramatic increase in
improvement rates was observed with the advent of
immunomodulatory drugs and proteasome inhibitors, and if
this trend continues the 5-year survival rate or a patient
diagnosed in 2014 would be approximately 66% [3]. Theedgments on page 1937.
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ty for Blood and Marrow Transplantation.tion, sequence, and duration of therapies, and in the modern
era for MM treatment, transplant trials strongly support the
use of upfront ASCT in the context of novel agents [4-6]. Until
proven otherwise, ASCT remains the standard of care for
eligible patients [7,8].
Despite these great advances, MM is widely considered
incurable, although some investigators have recently chal-
lenged this dogma [9]. The attainment of the deepest
response after both induction therapy and ASCT is one of the
strongest predictors of long-term outcomes [10-13] and
represents a major endpoint of current treatment strategies.
Novel agents are routinely used before ASCT as part of
induction therapy to increase response rates [4-6,12]. These
novel agents have also been added after ASCT as consolida-
tion [14-16] and maintenance [15-17] therapies to further
increase the quality of response.
The current standard conditioning regimen is high-dose
MEL [18-20], and ASCT may be single or tandem [2,21,22].
Table 1
Summary of Baseline Characteristics of Patients (N ¼ 64)
Characteristics Value
Median age, yr (range) 56 (24-70)
Male gender 37 (58%)
Durie-Salmon stage of myeloma on diagnosis
II 19 (30%)
III 45 (70%)
ISS stage of myeloma on diagnosis
I 20 (30%)
II 32 (50%)
III 6 (10%)
Unknown 6 (10%)
FISH analysis for cytogenetic abnormalities*
Absence of del(13q), t(4;14), or del(17p) 33 (66%)
Presence of del(13q) 12 (24%)
Presence of t(4;14) with or without del(17p) 5 (10%)
Monoclonal protein type
IgG 64%
IgA 26%
Light chain only 10%
ISS indicates International Staging System; FISH, ﬂuorescein in situ
hybridization.
* Fifty patients were available for assessment.
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regiment side of the HDC procedure [23-32]. The aim of the
present study is to evaluatewhether a second ASCTwithMEL
and thiotepa (THIO) is safe and can increase the rate of
response in patients with newly diagnosed MM whose ﬁrst
conditioning regimen only included MEL.
METHODS
Eligibility Criteria
Patients with symptomatic, measurable, and newly diagnosed MM age
70 years or younger were eligible for this trial. Other inclusion criteria
were a Eastern Cooperative Oncology Group performance status score of
at least 2 (on a scale from 0 to 5, with higher scores indicating greater
disability) and a life expectancy longer than 6 months, an absolute
neutrophil count (ANC) > 1500/mm3, and a platelet count > 75,000/mm3
[33], with normal cardiac and pulmonary function ﬁndings and adequate
renal function (creatinine clearance  30 mL/min). The main exclusion
criteria included a history of other cancers within the past 3 years and
peripheral neuropathy of grade 2 or higher.
Study Design
This multi-institutional, single-arm, prospective phase II study was
performed at the Hematology and Stem Cell Unit, La Maddalena Hospital,
Palermo, Italy; at the Hematology and Stem Cell Transplant Unit, Reggio
Calabria, Italy; and at the Hematology Unit, National Tumor Institute,
Naples, Italy. The study was approved by the institutional review boards of
the participating centers and was conducted according to the Declaration of
Helsinki and the International Conference on Harmonisation Guidelines for
Good Clinical Practice. All patients provided written informed consent.
All patients received a bortezomib-based induction therapy [34].
Patients who had a refractory disease (progression or no response) to
induction chemotherapy were excluded. High-dose cyclophosphamide (3 to
4 g/m2) and granulocyte colony-stimulating factor were used to mobilize
stem cells. The minimum target dose of CD34þ cells, to safely support 2
sequential courses of high-dose therapy, was 8  106/kg.
Four to 6 weeks after the administration of HDC, patients received MEL
(200 mg/m2), given as a single i.v. dose (day 2), followed by a peripheral
blood stem cell infusion (2  106 CD4þ cells/kg) 48 hours later (day 0).
Three to 6 months after the ﬁrst autotransplantation, patients with at least
stable disease received a second ASCT with THIO/MEL as the conditioning
regimen. THIO/MEL was administered as follows: THIO 275 mg/m2 on
day 5 and MEL 140 mg/m2 i.v. on day 2. Autologous peripheral blood
stem cells (2  106 CD4þ cells/kg) were infused on day 0. No consolidation
or maintenance therapies were permitted.
Supportive Care
During the aplastic phase in both ASCT procedures, all patients received
oral prophylaxis with ciproﬂoxacin at 500 mg twice daily or levoﬂoxacin at
500 mg/day from day 0 until neutrophil recovery and with acyclovir at 800
mg twice daily from day þ3 post-transplantation until approximately
day þ90. Pneumocystis jiroveci prophylaxis with trimethoprim/sulfameth-
oxazole, 1 double-strength tablet 2 or 3 times weekly, was started after
hematological recovery and continued for 3 months. Granulocyte colony-
stimulating factor (ﬁlgrastim or lenograstim) 5 mg/kg/day was started at
day þ5 until neutrophil recovery. RBC and platelet transfusions were given
to maintain hemoglobin levels  8 g/dL and platelet counts  10  109/L or
in case of symptomatic anemia and/or minimal mucocutaneous hemor-
rhagic syndrome. Patients received i.v. hydration and electrolyte support as
per institutional policy.
Evaluation of Response and Toxicity
The primary objective of this study was to evaluate treatment-related
toxicity and treatment-related mortality (TRM), time to neutrophil and
platelet engraftment after THIO/MEL, and cumulative incidence of neutro-
phil and platelets recovery. Secondary objectives were to evaluate the
complete response (CR) rate, the overall response rate (deﬁned as CR þ very
good partial response [VGPR]), progression-free survival (PFS), and OS. The
evaluation of response occurred at enrollment and at days þ30 and þ100
after both ASCTs. Moreover, we compared toxicities and engraftment rate
between the ﬁrst and second transplant.
Adverse events were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (version 3.0; http://
ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.
pdf). Time to neutrophil engraftment was deﬁned as the duration between
day 0 and the ﬁrst of 3 consecutive days of ANC> .5109/L after transplant.
Time to platelet engraftment was deﬁned as the duration between day 0 and
the ﬁrst day of platelet count sustained at >20  109/L without transfusionin the previous 7 days. TRM was deﬁned as mortality from any cause other
than disease progression within 100 days from transplantation.
Response and progression were reported by investigators according to
criteria of the European Group for Blood and Marrow Transplantation
(EBMT) [35] with the addition of a category for VGPR (90% reduction in
serum M protein and <100 mg urine M protein per day) [36]. Bone marrow
biopsy and aspirate samples were obtained at baseline and as needed to
conﬁrm CR. Patients with CR who lacked conﬁrmation from bone marrow
biopsy samples were downgraded to VGPR.
Statistical Analysis
Datawere summarized asmedian and range (continuous variables) or as
absolute frequencies and percentages (binary variables), as appropriate.
Within-patient comparisons were made by the Wilcoxon rank test (for
continuous variables) and the McNemar test (binary date), as appropriate.
Response rates, survival, and toxicity were summarized by descriptive sta-
tistics. TRM was evaluated as cumulative incidence. PFS and OS were
investigated by the Kaplan-Meier method. The response rate after THIO/MEL
was calculated and compared with MEL (200 mg/m2) response rates. The
degree of uncertainty (precision) around PFS and OS was expressed as point
estimate and the corresponding 95% conﬁdence interval. Data analysis was
performed by SPSS for Windows (version 20.0.0; IBM, Armonk, NY).
RESULTS
Study Population
Sixty-four consecutive transplant-eligible patients who
had received prior bortezomib-based induction therapy for
MM and with sensitive disease were enrolled and consti-
tuted the treatment population. All patients were followed
for toxicity, stem cell engraftment, and treatment response.
Patient baseline demographics and disease characteristics
are summarized in Table 1. Brieﬂy, patients had a median age
of 56 (range, 24 to 70) and 58% were men. Intermediate
(stage II) or high-risk (stage III) disease was present in 75%
of patients deﬁned by Durie-Salmon criteria and in 55% of
patients as deﬁned by the International Staging System. Data
on cytogenetic abnormalities, del(13q), t(4;14), and del(17p),
detected by ﬂuorescence in situ hybridization on highly
puriﬁed bone marrow plasma cells were available in 78% of
patients. The isotype distribution of M-proteins reﬂected the
typical MM population (IgG, 64%; IgA, 26%; free light chain
only, 10%).
Stem Cell Engraftment
The median number of CD34þ cells reinfused was 5.1 
106/kg (range, 3.3 to 7.1). All patients were successfully
Table 3
Treatment-Related Toxicity
Second
Transplant
(THIO/MEL
Conditioning
Regimen)
First
Transplant (MEL
Conditioning
Regimen)
P
Number of transplants 64 64
Fever  38.2C 25 (39%) 21 (33%) n.s
Fever origin n.s
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platelet engraftment were 11 (range, 9 to 17) and 12 (range,
10 to 22), respectively. Median number of days with ANC <
500/mL was 6 (range, 4 to 13). The transfusion requirements
stood at 1 (range, 0 to 5) and 1 (range, 0 to 3) for RBC and
platelet units, respectively. The engraftment kinetics seen for
THIO/MEL conditioning at second transplant were similar to
those reported previously with the ﬁrst MEL (200 mg/m2)
conditioning regimen (Table 2).FUO 18 (28%) 16 (25%)
CVC related 0 0
Clinically documented 2 (3%) 2 (3%)
Microbiologically documented
infection
5 (8%) 3 (5%)
No. of days of fever  38.2C,
median (range)
3 (1-22) 3 (2-18) n.s
No. of days antibiotic therapy,
median (range)
6 (0-25) 6 (0-18) n.s.
Gastrointestinal toxicity
Mucositis grades 3-4 6 (9%) 8 (12%) n.s
Hepatic toxicity, grade 3 3 (5%) 4 (6%) n.s.
Diarrhea, grade 3 4 (6%) 4 (6%) n.s.
Number of RBC transfusions,
median (range)
1 (0-5) 0 (0-11) .04
Number of PLT transfusions,
median (range)
1 (0-3) 1 (0-6) n.s
FUO indicates fever of unknown origin; CVC, central venous catheter; PLT,
platelet.Nonhematological Toxicity
All subjects were followed from day 0 through day þ180
postesecond transplant for nonhematological toxicity. After
THIO/MEL, nearly all patients experienced mild nausea or
vomiting (84.4%); however, there were only 6.3% grade 3
toxicities. The incidence of mucositis was 86%; only 6 of 64
patients (9%) experienced grades 3 to 4 mucositis. There
were 3 cases of hepatic toxicity (grades 3 to 4), and the
incidence of diarrhea (grades 3 to 4) was 6%. Twenty-ﬁve
patients (39%) had a fever. Infections documented by imag-
ing studies, such as chest radiographs, and physical exami-
nation in the absence of positive cultures were reported in 3%
of febrile episodes. A causative organism was identiﬁed in 5
(8%), including 2 with Streptococcus mitis bacteremia, 1 with
Escherichia coli bacteremia, 1 with microsporidia enteroco-
litis, and 1 with rotavirus enterocolitis, all of which resolved
with antibiotic therapy. We did not observe any cardiac or
renal toxicity. There was no TRM (Table 3).Response Assessment
Responses to induction therapy before and after ASCT
are shown in Figure 1. At the end of induction therapy, 26.6%
and 37.5% of the patients had achieved a CR and a VGPR,
respectively. After the ﬁrst and second transplantation, the
CR improved to 35.9% and 43.8%, respectively. Overall
response rates were 75% after the ﬁrst transplant and 86%
after the second transplant (P < .001) (Figure 1). After a
median of 18.1 months (range, 6.3 to 33.6) of follow-up after
the second ASCT, 13 patients had progressed and 3 died
fromMM. Median PFS was not reached, and actuarial 2-year
PFS rate was 71% (95% conﬁdence interval, 53% to 88%)
(Figure 2). Median OS was not reached. Actuarial 2-year OS
rate was 88.9% (95% conﬁdence interval, 76% to 100%)
(Figure 3).Table 2
Engraftment and Transplant Data
Second
Transplant
(THIO/MEL
Conditioning
Regimen)
First
Transplant (MEL
Conditioning
Regimen)
P
Number of transplants 64 64
CD34þ cells infused, median 
106/kg (range)
5.1 (3.3-7.1) 5 (2.1-6.1) n.s
Time to neutrophil engraftment,*
median days (range)
11 (9-17) 11 (9-20) n.s.
Time to platelet engraftment,y
median days (range)
12 (10-22) 12 (10-20) n.s
Duration of hospitalization,
median days (range)
16 (14-30) 15 (14-35) n.s.
n.s. indicates not signiﬁcant.
* Time to neutrophil engraftment was deﬁned as the duration between
day 0 and the ﬁrst of 3 consecutive days of ANC > .5  109/L.
y Time to platelet engraftment was deﬁned as the duration between day
0 and the ﬁrst day of platelet count sustained at >20  109/L.DISCUSSION
Evenwith major changes in the treatment of MM patients
with the introduction of novel agents, ASCT continues to play
a primary role in the armamentarium of anti-MM therapy
[4,5,7,8]. High-dose MEL is the most widely used drug as a
preparative regimen for ASCT in MM [18] and MEL200 is
considered the gold standard schedule [19,20]. This regimen
was initially reported in the early 1990s by the Arkansas [37]
and the Royal Marsden group [38] when, in newly diagnosed
patients, the researchers reported a high CR rate with low
extramedullary toxicity. In a randomized study, Moreau et al.
[39] demonstrated that MEL at 200 mg/m2 improved PFS
and OS, when compared with the combination of MEL (140
mg/m2) with 8 Gy of total body irradiation. Other trials using
the intensiﬁcation of the MEL dose have not demonstrated a
signiﬁcant improvement in terms of outcome and were
associated with a higher incidence of side effects [40]. Tar-
geting exposure to MEL by using area under the curve in the
latter setting has become particularly appealing, as recently
reported [41].
A more effective conditioning regimen may induce
deeper responses and longer remission duration, and various
clinical trials were performed to improve the conditioning
regimens before ASCT [18,20,23-32]. One strategy added
more agents to MEL. The Spanish group prospectively
investigated whether the use of oral busulfan (BU) 12 mg/kg
plus MEL (140 mg/m2) (BU/MEL) resulted in a longer PFS
compared with MEL at 200 mg/m2 or MEL at 140 mg/m2
plus total body irradiation. The ﬁnal analysis showed that
conditioning with BU/MEL was associated with longer PFS
but equivalent OS, compared with that achieved with MEL
(200 mg/m2). However, this result should be counter-
balanced against the higher frequency of veno-occlusive
diseaseerelated deaths in the BU/MEL group [21].
An alternative to oral BU is i.v. BU. Blanes et al. [31]
compared i.v. BU 9.6 mg/kg and MEL (140 mg/m2) versus
MEL (200 mg/m2). The results showed a similar overall
response rate and CR/near Complete Remission rate in both
Figure 1. Day 100 response rates after transplant. PR indicates partial response.
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ever, longer among patients receiving BU/MEL when
compared with those receiving a MEL-only conditioning
regimen. No case of veno-occlusive disease was observed.
The same authors [32] analyzed the results of ASCT with
i.v. BU 9.6 mg/kg andMEL (140mg/m2) preparative regimens
in patients who had received a modern induction treatment
containing bortezomib. Overall response rate and CR after
transplant were 100% and 49%, respectively.
Mark et al. [26] conducted a phase I trial adding escalating
doses of bendamustine to MEL (200 mg/m2). A maximum
tolerated dose was not encountered, and the highest dose
level cohort of bendamustine 225 mg/m2 þ MEL was
expanded to further evaluate safety. The regimen did not
increase transplantation risk or toxicity, and no TRM wasFigure 2. Progressionreported. The authors reported an overall response rate of
80% at day þ100 and a CR or improved rate of approximately
45% at 1 year post-ASCT.
THIO is a polyfunctional alkylating agent, similar in
structure to nitrogen mustard, that damages the DNA of
cancer cells and was designated as an orphan drug by the
European Medicines Agency on January 29, 2007. High-dose
THIO appears to have broad-spectrum antitumor efﬁcacy
[42], which can be added in myeloablative multiagent regi-
mens for ASCT in both solid [43,44] and hematopoietic
tumors [45-48]; the drug was designated by the US Food and
Drug Administration as a conditioning treatment before
ASCT on April 2, 2007.
In our study the choice of THIO was based on the docu-
mented sensitivity of myeloma cells to the drug in the-free survival.
Figure 3. Overall survival.
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decision was made to explore a double alkylator-based
regimen. The dose-limiting toxicity of THIO is notably on
the gastrointestinal tract (mucositis and diarrhea) and the
central nervous system (drowsiness and seizure). In the
MM autologous setting, the recommended dose ranges from
150 mg/m2 per day to 250 mg/m2 per day, administered for
3 consecutive days before depending on the combination
with other chemotherapeutic medicinal products, without
exceeding the total maximum cumulative dose of 750
mg/m2, during the time of the entire conditioning treatment
(see www.ema.europa.eu/docs/en_GB/.../WC500090252.pdf.)
Results from an Israeli study [50] showed that treatment
with etoposide, THIO, and MEL in MMmay be more effective
than MEL alone before ASCT. In particular, patients who
received the 3-drug combination had a longer time to pro-
gression (44 versus 17 months) and longer OS (not yet
reached after a median of 108 months follow-up versus 59
months) than those who received MEL alone. However, the
researchers reported that the 3-drug combination appeared
to be more toxic than MEL alone.
We used a strategy of a tandem transplant in “de novo”
sensitive-disease patients and explored if the second trans-
plant with a double alkylator-based regimen (THIO þ MEL)
was feasible, safe, and efﬁcacious. The tandem ASCT
approach achieved an improvement in OS [2], even though a
survival beneﬁt was mainly seen in those patients who failed
to achieve at least a VGPR [21,22].In this trial the choice to administer THIO at 275 mg/m2
was made to reduce the risk of synergistic toxicity between
the MEL and THIO on the gastrointestinal tract. We decided
on in any case a myeloablative dosage. The engraftment
kinetics and toxicities, seen for THIO/MEL conditioning, are
similar to those reported previously with MEL (200 mg/m2)
conditioning, consisting primarily of mild mucositis and
gastrointestinal toxicity [18]. In our study, oral mucositis
occurred in 86% of subjects, with most patients experiencing
grades 1 to 2 mucositis. Given these data, the association of
THIO and MEL (140 mg/m2) does not appear to signiﬁcantly
increase mucositis risk compared with MEL at 200 mg/m2.
TRM was 0% at þ100 days post-transplantation. Further-
more, in the comparison between the ﬁrst and the second
transplant, there was no difference in terms of toxicity and
bone marrow engraftment.
It is too early to draw deﬁnitive conclusions regarding the
efﬁcacy of THIO in a tandem ASCT approach for MM. We
reported an overall response rate of 86% at day þ100 and
a CR rate of approximately 44% after THIO/MEL ASCT. The
2-year PFS and OS are on par with what is expected from
MEL200 in the new drug era.
There are some critical issues in the present study
because we evaluated the response using the EBMT registry
response criteria. Although the CR and the overall response
rates were not the main objective of the study, assessing the
response to treatment is a key determinant of MM treat-
ment. Recently, the International Myeloma Working Group
M. Musso et al. / Biol Blood Marrow Transplant 21 (2015) 1932e1938 1937response criteria were developed from EBMT/International
Bone Marrow Transplant Registry and Autologous Blood
and Bone Marrow Transplant Registry response criteria [35]
with revisions and improvements to help uniform reporting
[36,51]. It is recommended that the International Myeloma
Working Group uniform response criteria should be used in
future clinical trials. Free light chain testing can help to
demonstrate progressive improvements in the quality of
response, and the free light chain ratio is required for doc-
umenting stringent CR.
However, considering its good tolerability, THIO/MEL
could be an effective treatment option especially in elderly
MM patients. Moreover, stratiﬁcation of patients into various
risk groups based on the chromosomal markers is being used
by some centers for prognostic counseling, selection, and
sequencing of therapy approaches. The utility of this infor-
mation is to determine prognostic and clinical recommen-
dations as a more effective conditioning regimen.
Our study was not designed to carry out a detailed cost
analysis. However, the length of hospitalization accounted
for most of the costs of an autograft procedure. In this trial
the median duration of hospitalization was similar between
the ﬁrst and second transplant. For this reason it is likely that
the addition of THIO in the conditioning regimen does not
determine an increase in the cost of the procedure [52].
Following this study, we are going to evaluate the efﬁcacy
of the association between THIO and MEL200, which is the
current standard conditioning in MM patients [19]. Subse-
quently, the regimen should be explored for efﬁcacy in a
phase III study. The next randomized study should be plan-
ned to address safety, therapeutic activity, and cost efﬁcacy
of the 2 conditioning regimens.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Authorship statement: Study concepts by M.M., G.M., G.M.,
and M.M. Data acquisition by G.M., G.M., A.C., G.C., D.D., R.S.,
andM.M. Quality control of data and algorithms byM.M., A.C.
and M.M. Data analysis and interpretation by M.M., G.M.,
G.M., and M.M. Statistical analysis and manuscript prepara-
tion by M.M. and M.M. Manuscript editing by M.M., A.P., and
M.M. Manuscript review by M.M., G.M., G.M., A.C., G.C., R.S.,
D.D., A.P., and M.M.
REFERENCES
1. Cavagnaro F, Lein JM, Pavlovsky S, et al. Comparison of two combina-
tion chemotherapy regimens for multiple myeloma: methyl-CCNU,
cyclophosphamide, and prednisone versus melphalan and predni-
sone. Cancer Treat Rep. 1980;64:73-79.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized
trial of autologous bone marrow transplantation and chemotherapy in
multiple myeloma. Intergroupe Français du Myélome. N Engl J Med.
1996;335:91-97.
3. Bergsagel PL. Where we were, where we are, where we are going:
progress in multiple myeloma. Am Soc Clin Oncol Educ Book. 2014;
199-203.
4. Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalido-
mide, and dexamethasone (VTD) as induction pretransplantation
therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM
study. Blood. 2012;120:1589-1596.
5. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and
maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:
895-905.
6. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexa-
methasone is superior to vincristine plus doxorubicin plus dexametha-
sone as induction treatment prior to autologous stem-cell transplantation
in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase
III trial. J Clin Oncol. 2010;28:4621-4629.7. Shah N, Callander N, Ganguly S, et al. Hematopoietic stem cell trans-
plantation for multiple myeloma: guidelines from the American Society
for Blood and Marrow Transplantation. Biol Blood Marrow Transplant.
2015;21:1155-1166.
8. Martino M, Morabito F. Autologous stem cell transplantation in mul-
tiple myeloma is not dead but alive and well. Expert Opin Biol Ther.
2015;15:149-154.
9. Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last:
deﬁning criteria and providing the evidence. Blood. 2014;124:
3043-3051.
10. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least
very good partial response is a simple and robust prognostic factor in
patients with multiple myeloma treated with high-dose therapy: long-
term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol. 2009;27:
5720-5726.
11. Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic
signiﬁcance of response in multiple myeloma after stem cell trans-
plantation. Blood. 2011;118:529-534.
12. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide
plus dexamethasone compared with thalidomide plus dexamethasone
as induction therapy before, and consolidation therapy after, double
autologous stem-cell transplantation in newly diagnosed multiple
myeloma: a randomised phase 3 study. Lancet. 2010;376:2075-2085.
13. Martino M, Postorino M, Gallo GA, et al. Long-term results in multiple
myeloma after high-dose melphalan and autologous transplantation
according to response categories in the era of old drugs. Clin Lymphoma
Myeloma Leuk. 2014;14:148-154.
14. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexa-
methasone is superior to thalidomide-dexamethasone as consolida-
tion therapy after autologous hematopoietic stem cell transplantation
in patients with newly diagnosed multiple myeloma. Blood. 2012;
120:9-19.
15. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line trans-
plantation program with lenalidomide, bortezomib, and dexametha-
sone combination as induction and consolidation followed by
lenalidomide maintenance in patients with multiple myeloma: a phase
II study by the Intergroupe Francophone du Myélome. J Clin Oncol.
2014;32:2712-2717.
16. Gentile M, Vigna E, Recchia AG, et al. Role of new drugs incorporated
into consolidation and maintenance therapy in transplant-eligible
multiple myeloma patients. Expert Opin Pharmacother. 2014;15:
1315-1320.
17. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-
cell transplantation for multiple myeloma. N Engl J Med. 2012;366:
1770-1781.
18. Martino M, Olivieri A, Ofﬁdani M, et al. Addressing the questions
of tomorrow: melphalan and new combinations as conditioning
regimens before autologous hematopoietic progenitor cell trans-
plantation in multiple myeloma. Expert Opin Invest Drugs. 2013;22:
619-634.
19. Giralt S. 200 mg/m(2) melphalan-the gold standard for multiple
myeloma. Nat Rev Clin Oncol. 2010;7:490-491.
20. Moreau P, Attal M, Harousseau JL. New developments in conditioning
regimens before auto-SCT in multiple myeloma. Bone Marrow Trans-
plant. 2011;46:911-915.
21. Harousseau JL. Hematopoietic stem cell transplantation in multiple
myeloma. J Natl Compr Canc Netw. 2009;7:961-970.
22. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of
single compared with double autologous stem-cell transplantation for
multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:
2434-2441.
23. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Busulfan 12 mg/kg plus
melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning
regimens for autologous transplantation in newly diagnosed multiple
myeloma patients included in the PETHEMA/GEM2000 study. Haema-
tologica. 2010;95:1913-1920.
24. Somlo G, Spielberger R, Frankel P, et al. Total marrow irradiation: a
new ablative regimen as part of tandem autologous stem cell trans-
plantation for patients with multiple myeloma. Clin Cancer Res. 2011;
17:174-182.
25. Lin SC, Hsieh PY, Shueng PW, et al. Total marrow irradiation as part of
autologous stem cell transplantation for Asian patients with multiple
myeloma. Biomed Res Int. 2013;2013:321762.
26. Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bend-
amustine and melphalan conditioning for autologous stem cell
transplantation in multiple myeloma. Biol Blood Marrow Transplant.
2013;19:831-837.
27. Miyamoto T, Yoshimoto G, Kamimura T, et al. Combination of high-
dose melphalan and bortezomib as conditioning regimen for autolo-
gous peripheral blood stem cell transplantation in multiple myeloma.
Int J Hematol. 2013;98:337-345.
28. Byrne M, Wingard JR, Moreb JS. Continuous infusion cyclophospha-
mide and low-dose total body irradiation is a safe and effective con-
ditioning regimen for autologous transplant in multiple myeloma.
Transplant Proc. 2013;45:3361-3365.
M. Musso et al. / Biol Blood Marrow Transplant 21 (2015) 1932e1938193829. Freytes CO, Toro JJ, Yeh RF, et al. Safety and efﬁcacy of targeted-dose
busulfan and bortezomib as a conditioning regimen for patients with
relapsed multiple myeloma undergoing a second autologous blood
progenitor cell transplantation. Biol Blood Marrow Transplant. 2014;20:
1949-1957.
30. Wang TF, Fiala MA, Cashen AF, et al. A phase II study of V-BEAM as
conditioning regimen before second auto-SCT for multiple myeloma.
Bone Marrow Transplant. 2014;49:1366-1370.
31. Blanes M, González JD, Lahuerta JJ, et al. Bortezomib-based induction
therapy followed by intravenous busulfan-melphalan as conditioning
regimen for patients with newly diagnosed multiple myeloma. Leuk
Lymphoma. 2015;56:415-419.
32. Blanes M, Lahuerta JJ, González JD, et al. Intravenous busulfan and
melphalan as a conditioning regimen for autologous stem cell trans-
plantation in patients with newly diagnosed multiple myeloma: a
matched comparison to a melphalan-only approach. Biol Blood Marrow
Transplant. 2013;19:69-74.
33. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:
1046-1060.
34. Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus
nonbortezomib-based induction treatment before autologous stem-cell
transplantation in patients with previously untreated multiple
myeloma: a meta-analysis of phase III randomized, controlled trials.
J Clin Oncol. 2013;31:3279-3287.
35. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease
response and progression in patients with multiple myeloma treated
by high-dose therapy and haemopoietic stem cell transplantation.
Myeloma Subcommittee of the EBMT. European Group for Blood and
Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
36. Durie BG, Harousseau JL, Miguel JS, et al. International uniform
response criteria for multiple myeloma. International Myeloma
Working Group. Leukemia. 2006;20:1467-1473.
37. Jagannath S, Vesole DH, Glenn L, et al. Low-risk intensive therapy for
multiple myeloma with combined autologous bone marrow and blood
stem cell support. Blood. 1992;80:1666-1672.
38. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and
autologous bone marrow transplantation as consolidation in previ-
ously untreated myeloma. J Clin Oncol. 1994;12:759-763.
39. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2)
melphalan and 8 Gy total body irradiation plus 140 mg/m(2)
melphalan as conditioning regimens for peripheral blood stem cell
transplantation in patients with newly diagnosed multiple myeloma:
ﬁnal analysis of the Intergroupe Francophone du Myélome 9502 ran-
domized trial. Blood. 2002;99:731-735.
40. Phillips GL, Meisenberg BR, Reece DE, et al. Activity of single-agent
melphalan 220-300 mg/m2 with amifostine cytoprotection andautologous hematopoietic stem cell support in non-Hodgkin and
Hodgkin lymphoma. Bone Marrow Transplant. 2004;33:781-787.
41. Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much-just right!
(Better ways to give high dose melphalan). Bone Marrow Transplant.
2014;49:1457-1465.
42. Wolff SN, Herzig RH, Fay JW, et al. High-dose N,N0 ,N00-triethylene-
thiophosphoramide (thiotepa) with autologous bone marrow trans-
plantation: phase I studies. Semin Oncol. 1990;17(1 Suppl. 3):2-6.
43. Martino M, Ballestrero A, Zambelli A, et al. Long-term survival in pa-
tients with metastatic breast cancer receiving intensiﬁed chemo-
therapy and stem cell rescue: data from the Italian registry. Bone
Marrow Transplant. 2013;48:414-418.
44. Pedrazzoli P, Martinelli G, Gianni AM, et al. Adjuvant high-dose
chemotherapy with autologous hematopoietic stem cell support for
high-risk primary breast cancer: results from the Italian national reg-
istry. Biol Blood Marrow Transplant. 2014;20:501-506.
45. Di Ianni M, Ballanti S, Iodice G, et al. High-dose thiotepa, etoposide and
carboplatin as conditioning regimen for autologous stem cell trans-
plantation in patients with high-risk Hodgkin’s lymphoma. Hematolo-
gy. 2012;17:23-27.
46. Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan,
melphalan and thiotepa conditioning in autologous hematopoietic
stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk
Lymphoma. 2014;55:583-587.
47. Ganguly S, Jain V, Divine C, et al. BU, melphalan and thiotepa as a
preparative regimen for auto-transplantation in Hodgkin’s disease.
Bone Marrow Transplant. 2012;47:311-312.
48. Falzetti F, Di Ianni M, Ballanti S, et al. High-dose thiotepa, etoposide
and carboplatin as conditioning regimen for autologous stem cell
transplantation in patients with high-risk non-Hodgkin lymphoma.
Clin Exp Med. 2012;12:165-171.
49. Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan,
and cyclophosphamide: a new preparative regimen for autologous
marrow or blood stem cell transplantation in high-risk multiple
myeloma. Blood. 1993;82:2324-2328.
50. Abu Zaid B, Abdul-Hai A, Grotto I, et al. Autologous transplant in
multiple myeloma with an augmented conditioning protocol. Leuk
Lymphoma. 2013;54:2480-2484.
51. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma
Working Group consensus statement for the management, treatment,
and supportive care of patients with myeloma not eligible for stan-
dard autologous stem-cell transplantation. J Clin Oncol. 2014;32:
587-600.
52. Barosi G, Marchetti M, Alessandrino P, et al. A model for analysing the
cost of autologous peripheral blood progenitor cell (PBPC) trans-
plantation. Bone Marrow Transplant. 1999;23:719-725.
